Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

US FDA Clears Propeller Integration With GlaxoSmithKline PLC (ADR) (GSK)’s Ellipta

The US Food and Drug Administration (FDA) has recently cleared the Propeller platform of Propeller Health for use with GlaxoSmithKline Plc (ADR) (NYSE:GSK)‘s Ellipta dry powder inhaler (DPI), fulfilling the agreement between the two companies.

What US FDA Clearance Means for the Companies

“The inclusion of GSK’s Ellipta inhaler in Propeller’s digitally-guided therapy platform is an important step in our goal of modernizing the management of respiratory disease,” emphasized David Van Sickle, Propeller Health CEO.

The US FDA has cleared Propeller to help patients and healthcare providers alike to gain a deeper understanding of asthma, with the primary objective of being able to relieve symptoms and improve patient outcomes. As Dave Allen, GSK Head of Respiratory Research and Development (R&D) has explained, the Propeller integration in Ellipta will provide real-time and accurate patient interaction information. Consequently, healthcare providers can acquire valuable insights that will be beneficial in patient management.

Encouraged by the US FDA clearance, the two companies hope to bring Propeller for Ellipta to the global market soon.

pharmacist, worker, shelves, business, counter, glasses, attractive, medical, competence, chemist, adult, clinic, drugstore, selling, female, consultation, medicine, coat


Q3 Financial Results

In other news, GlaxoSmithKline Plc (ADR) (NYSE:GSK) issued its third quarter earnings report last month.

The company posted £7.50 billion in group sales. Its Pharmaceuticals segment brought in £4.10 billion; the Consumer Healthcare segment brought in £1.90 billion; the Vaccines segment contributed £1.60 billion; and the New Product Sales segment contributed £1.21 billion.

New Product Sales have been driven by the strong sales of Tivicay, Triumeq, Anoro, Breo, Incruse, Nucala, Bexsero, and Menveo.

Andrew Witty, GSK CEO, believes that the results reflect a compelling third quarter performance overall. New Product Sales met initial expectations. Consequently, GSK is confident about meeting its outlook for the full 2016 year.

Presently, Pharmaceuticals, Consumer Healthcare, and Vaccines are the three major business segments of GlaxoSmithKline Plc (ADR) (NYSE:GSK) across more than 150 countries. In 2015, Pharmaceuticals made up 58% of its revenue; Consumer Healthcare made up 26%; and Vaccines made up 16%.

On Monday, GSK gained 0.54% to close the session at $38.84.

Follow Glaxosmithkline Plc (NYSE:GSK)
Trade (NYSE:GSK) Now!

Note: This article is written by Adam Russell and was originally published at Market Exclusive.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.